Open-Label Extension Study to Pioneer Study 6058-SCD-101
NCT07401823
·
clinicaltrials.gov ↗
PHASE2
Phase
ENROLLING_BY_INVITATION
Status
50
Enrollment
INDUSTRY
Sponsor class
Conditions
Sickle Cell Disease
Interventions
DRUG:
Pociredir
Sponsor
Fulcrum Therapeutics